London, 16 April 2026 — The British Business Bank has agreed a £100 million cornerstone commitment to Apposite Healthcare Growth I, a new fund aimed at scale-stage UK health technology and life sciences companies. The commitment is the Bank's largest single fund allocation to date and its first deal with specialist healthcare investor Apposite Capital.
Apposite Healthcare Growth I will invest across medical products, diagnostics, life sciences tools, digital health and pharmaceutical outsourcing services, with a primary focus on UK companies approaching a growth inflection point. The stated aim is to address a shortage of scale-up capital that pushes British life sciences companies toward early acquisition or overseas capital before they reach full commercial maturity.
The investment sits within a broader shift in the Bank's strategy. Over the next five years it plans to back the launch of ten new growth-stage funds and direct more than 60 percent of its venture and growth flow toward scale-ups, writing larger cheques into fewer managers to try to crowd institutional capital in alongside it.
The UK needs growth stage funding, and the Bank is stepping up to deliver this. Working with the UK's venture capital community, we are looking to support the creation of growth stage funds capable of writing significant cheques into the next generation of UK unicorns.
Sam Gray, Managing Partner at Apposite Capital, said the commitment would allow the firm to continue backing ambitious growing companies in healthcare. Apposite was founded in 2006 and has a twenty-year track record in European healthcare and life sciences investment.
The commitment from the British Business Bank will enable Apposite to continue its strong track record of supporting ambitious growing companies and investing in businesses that can achieve better healthcare for more people. This fund will bridge the scale-up gap, enabling high potential companies to accelerate their growth, commercialise transformative technologies and improve health outcomes.
Peter Kyle, Secretary of State for Business and Trade, linked the announcement to a wider political commitment to domestic innovation.
This record investment into Apposite Capital delivers on that promise by giving it the financial firepower to support the UK's most exciting healthcare tech firms scale, develop cutting edge medical products and diagnostics, and improve healthcare right across the country.
The commitment does not carry an immediate product or policy change for the wider technology market. It signals where the Bank intends to concentrate its firepower in coming years: larger, later-stage cheques into UK growth managers, with life sciences as a priority vertical.
